Chemoprevention Trial of Selenium and Prostate Cancer

Abstract

The principal purpose of this trial is to assess the potential for the essential nutrient selenium (Se) to modulate biomarkers of prostate cancer between initial diagnostic biopsy and radical prostatectomy. The scope of work is to randomize at lest 110 participants to either a placebo or Se dosages of 200ug, or 400ug/day. Recruitment is continuing as a result of a no-cost extension. A total of 90 subjects have been randomized. Of these, 82 have completed the study, 7 dropped before completing the study, and 1 is in the process of completing the study.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Dec 01, 2003
Accession Number
ADA423159

Entities

People

  • Frederick R. Ahmann

Organizations

  • University of Arizona

Tags

DTIC Thesaurus Topics

  • African Americans
  • Biological Markers
  • Biomedical Research
  • Cells
  • Clinical Trials
  • Data Analysis
  • Drug Therapy
  • Medical Personnel
  • Neoplasms
  • North America
  • Prostate
  • Prostate Cancer
  • Questionnaires
  • Selenium
  • Standards
  • Tissues
  • Vitamin E

Fields of Study

  • Medicine

Readers

  • Clinical Trial Research.
  • Prostate Cancer Biology.

Technology Areas

  • Biotechnology